Key Highlights
- Full-Year Revenue of Syngenta Group: $28.8 billion, down 10% year-over-year (-7% CER).
- EBITDA: $3.9 billion, down 15% (-1% CER).
- Q4 EBITDA: Increased 11% year-over-year (+38% CER) to $1.1 billion.
- Channel Destocking: Largely complete, setting stage for potential recovery in 2025.
- Digital Agriculture: Expansion of digital platforms and launch of AI-based tools for yield optimization.
Overall Syngenta Group Performance
Syngenta Group announced its full-year and Q4 2024 results, reporting annual revenue of $28.8 billion, representing a 10% decline year-over-year, or 7% at constant exchange rates (CER). EBITDA declined by 15% to $3.9 billion (-1% CER). The reduction was attributed to challenging weather conditions, inventory adjustments in crop protection, price pressures, and unfavorable currency exchange rates.
In Q4 2024, the Group posted revenue of $7.5 billion (-5%, or -1% CER), while EBITDA grew by 11% (+38% CER) to $1.1 billion. Syngenta implemented cost-cutting and restructuring initiatives that supported margin recovery and increased operational efficiency.
Syngenta Crop Protection
Financial Overview
- 2024 Revenue: $13.2 billion (-13%, or -9% CER)
- Q4 Revenue: $3.7 billion (-6%, +1% CER)
Sales in North America dropped 24%, Latin America fell 10%, and Europe declined 12%. Asia, Middle East & Africa saw a 13% decline, while China posted a 7% increase.
Product Innovations
- Continued success with PLINAZOLIN® insecticide and ADEPIDYN® fungicide.
- TYMIRIUM® launched in China, Australia, and Peru.
- Strong sales in biologicals and digital tools, such as CROPWISE® AI, with the platform now covering 70 million hectares.
ADAMA Performance
Financial Overview
- 2024 Revenue: $4.1 billion (-11%, or -8% CER)
- Q4 Revenue: $1.1 billion (-2%, +2% CER)
Sales declines were noted across Latin America (-20%) and Asia-Pacific (-15%). North America grew 4%.
Strategic Transformation
ADAMA’s transformation plan in 2024 led to margin improvement and EBITDA growth. The company focused on cost reductions and prioritization of key markets.
Product Launches
- FORPIDO® launched in India for rice cultivation.
- GILBOA®™ fungicide submitted to FRAC.
- Continued expansion of prothioconazol fungicide portfolio.
Syngenta Group’s Seeds Division
Financial Overview
- 2024 Revenue: $4.8 billion (flat, +2% CER)
- Q4 Revenue: $1.5 billion (+4%, +7% CER)
Sales increased in North America (+3%) and China (+18%), while Latin America (excluding Brazil), Asia, and Europe posted declines.
Product Developments
- Launch of BYDV-resistant hybrid barley in Europe.
- Growth in biotech corn across Asia.
- Exclusive licensing deal with Emerald Seed Company to expand onion seed portfolio.
Syngenta Group China
Financial Overview
- 2024 Revenue: $9.6 billion (-9%, or -7% CER)
- Q4 Revenue: $1.9 billion (-7%, or -8% CER)
Despite a revenue decline, Syngenta Group China achieved record EBITDA due to strategic focus on high-margin products.
Business Highlights
- Sales of seeds grew 18%, maintaining market leadership.
- Crop protection sales increased 2%, driven by demand for biologicals and new technologies.
- Continued GM trait approvals: 2 corn, 1 soybean.
Summary Financials of Syngenta Group
Full-Year 2024 vs. 2023 (USD)
| Metric | 2024 | 2023 | % Change |
|---|---|---|---|
| Sales | $28.8B | $32.2B | -10% |
| EBITDA | $3.9B | $4.6B | -15% |
Q4 2024 vs. Q4 2023 (USD)
| Metric | Q4 2024 | Q4 2023 | % Change |
| Sales | $7.5B | $7.9B | -5% |
| EBITDA | $1.1B | $1.0B | +11% |
Syngenta Group aims to leverage ongoing innovation, operational efficiency, and digital agriculture tools to support future profitability. With inventory normalization and stabilization across markets, the company anticipates improved performance beginning in the second half of 2025.
Discover the entire financials here.
6 Comments